This was always the most likely outcome for the DSMB meeting. I had my fingers crossed because I just don't believe we can demonstrate what we need to do to get approved for M/M with the number of patient data we unblinded. Hope I'm wrong, and we should see that data soon. What will look like clear efficacy to most of us is unlikely to sway the FDA , IMO. We'll still have the interim look in a couple of months, and let's hope we aren't asked to fully enroll that to 390.

Next goal- uplisting this month.